Linaclotide Acetate

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Irritable Bowel Syndrome With Constipation

Drug Information

Target Indication

Irritable Bowel Syndrome With Constipation

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA11/26/2012

Constella

Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.

Drug Science

Mechanism of action & safety profile

Developer

IRWD

IRONWOOD PHARMACEUTICALS INC

Related Pipeline

Gastroesophageal Reflux Disease (GERD)

Irritable Bowel Syndrome With Constipation

Gastroesophageal Reflux Disease

Irritable Bowel Syndrome With Diarrhea (IBS-D)

Diabetic Gastroparesis

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts